Vol. 21 No. 1 (2017)
ENDOVASCULAR SURGERY: SPECIAL TOPIC

Long-term clinical outcomes for bifurcation treatment using a provisional T-stenting and double proximal optimization technique with Absorb bioresorbable scaffolds

PDF (Русский)
  • R. Ivanchenko,
  • A. Birukov,
  • K. Smirnov
R. Ivanchenko
Pavlov First Saint Petersburg State Medical University, 197022 Saint Petersburg, Russian Federation
Bio
A. Birukov
Pavlov First Saint Petersburg State Medical University, 197022 Saint Petersburg, Russian Federation
K. Smirnov
Pavlov First Saint Petersburg State Medical University, 197022 Saint Petersburg, Russian Federation
DOI: https://doi.org/10.21688/1681-3472-2017-1-50-55

Published 2017-04-25

Keywords

  • bioresorbable scaffolds,
  • bifurcation lesions,
  • coronary artery,
  • optical coherence tomography

How to Cite

Ivanchenko, R., Birukov, A., & Smirnov, K. (2017). Long-term clinical outcomes for bifurcation treatment using a provisional T-stenting and double proximal optimization technique with Absorb bioresorbable scaffolds. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 21(1), 50–55. https://doi.org/10.21688/1681-3472-2017-1-50-55

Copyright (c) 2017 Ivanchenko R.D., Birukov A.V., Smirnov K.A.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Aim. The article presents long-term outcomes of treatment of coronary artery bifurcation lesions by using bioresorbable vascular scaffolds and provisional T-stenting combined with double proximal optimization.
Methods. 14 patients aged 44-80 years (mean age 61±6 years) including 8 (57.14 %) males underwent endovascular treatment of coronary artery bifurcation lesions by using Absorb bioresorbable vascular scaffolds (BVS). Clinical/instrumental analysis was carried out after 23.7±4.12 months. Angiographic examination was performed in 12 cases (85.71 %). 7 patients (50 %) underwent optical coherent tomography.
Results. 11 patients (78.57) were free of angina during long-term follow-up. 1 patient (7.14 %) developed BVS thrombosis and received a drug-eluting stent. A neointimal layer of the main branch increased during long-term follow-up to 29.23±7.82%, that of the lateral branch – up to 19.2±7.48%. Optical coherence tomography (OCT) shows that all strata are fully covered with neointima, the number of strata with malappositions is minimal and the loss of the main branch diameter (16.9±4.9%) is insignificant.
Conclusion. The use of Absorb bioresorbable vascular scaffolds implanted by means of provisional T-stenting combined with double proximal optimization when treating coronary artery bifurcation lesions is a safe and efficient procedure.

Received 2 February 2017. Accepted 10 March 2017.

Financing: The study did not have sponsorship.
Conflict of interest: The authors declare no conflict of interest.

PDF (Русский)

References

  1. Colombo A., Stankovic G. Problem oriented approaches in Interventional Cardiology. London: Informa Healthcare; 2007. p. 37-57.
  2. Ge L., Airoldi F., Iakovou I., Cosgrave J., Michev I., Sangiorgi G.M., Montorfano M., Chieffo A., Carlino M., Corvaja N., Colombo A. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation. J Am Coll Cardiol. 2005;46(4):613-620.
  3. Lefevre T., Louvard Y., Morice M.C. Current approach to coronary bifurcation stenting. In: J. Marco, P. Serruys, G. Biamino et al. The Paris Course on revascularization. Europe Edition, Paris; 2002. p. 51-77.
  4. Serruys R.W., Kutryk M.J., Ong A. Coronary-artery stent. N Eng J Med. 2006;354(5):483-495.
  5. Serruys P.W., Chevalier B., Dudek D., Cequier A., Carrie D., Iniguez A., Dominici M., van der Schaaf R.J., Haude M., Wasungu L., Veldhof S., Peng L., Staehr P., Grundeken M.J., Ishibashi Y., GarciaGarcia H.M., Onuma Y. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385(9962):43-54. http://dx.doi.org/10.1016/S0140-6736(14)61455-0
  6. Ellis S.G., Kereiakes D.J., Metzger D.C., Caputo R.P., Rizik D.G., Teirstein P.S., Litt M.R., Kini A., Kabour A., Marx S.O., Popma J.J., McGreevy R., Zhang Z., Simonton C., Stone G.W.; ABSORB III Investigators. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med. 2015;373(20):1905-15. http://dx.doi.org/10.1056/NEJMoa1509038
  7. Gao R., Yang Y., Han Y., Huo Y., Chen J., Yu B., Su X., Li L., Kuo H.C., Ying S.W., Cheong W.F., Zhang Y., Su X., Xu B., Popma J.J., Stone G.W.; ABSORB China Investigators. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. J Am Coll Cardiol. 2015;66(21):2298-309. http://dx.doi.org/10.1016/j.jacc.2015.09.054.
  8. Stone G.W., Gao R., Kimura T., Kereiakes D.J., Ellis S.G., Onuma Y., Cheong W.F., Jones-McMeans J., Su X., Zhang Z., Serruys P.W. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387(10025):1277-89. http://dx.doi.org/10.1016/S0140-6736(15)01039-9.
  9. Onuma Y., Sotomi Y., Shiomi H., Ozaki Y., Namiki A., Yasuda S., Ueno T., Ando K., Furuya J., Igarashi K., Kozuma K., Tanabe K., Kusano H., Rapoza R., Popma J.J., Stone G.W., Simonton C., Serruys P.W., Kimura T. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimuseluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. Eurointervention. 2016;12(9):1090-1101. http://dx.doi.org/10.4244/EIJY16M09_01